Eli Lilly (LLY) Total Debt (2009 - 2026)

Eli Lilly (LLY) has reported Total Debt for 18 consecutive years, with $43.4 billion the latest figure, recorded in Q1 2026.

• Total Debt for Q1 2026 came in at $43.4 billion, up 12.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.4 billion (up 12.6% YoY), and the FY2025 annual result was $42.5 billion, up 26.33% from the prior year.
• Total Debt was $43.4 billion for Q1 2026 at Eli Lilly, up from $42.5 billion in the prior quarter.
• Over five years, Total Debt peaked at $43.4 billion in Q1 2026 and troughed at $15.9 billion in Q3 2022.
• Average Total Debt over 5 years is $28.0 billion, with a median of $26.2 billion recorded in 2024.
• Year-over-year, Total Debt declined 7.01% in 2022 and jumped 55.34% in 2023.
• Over 5 years, Total Debt stood at $16.2 billion in 2022, then surged by 55.34% to $25.2 billion in 2023, then soared by 33.37% to $33.6 billion in 2024, then increased by 26.33% to $42.5 billion in 2025, then grew by 2.04% to $43.4 billion in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $43.4 billion in Q1 2026, $42.5 billion in Q4 2025, and $42.5 billion in Q3 2025.